FDA\'s CDER hires 633 new scientists

21 September 2008

The USA\'s Food and Drug Administration has met its target of recruiting over 1,300 staff by the end of September, in a drive to increase the federal government agency\'s work force by about 10%. The present campaign was launched in April and is the result of extra funding provided to the FDA for better monitoring of food and pharmaceutical products following the renewal of industry user fee legislation (Marketletters passim).

Previously, the FDA has blamed understaffing and the loss of crucial people to the private sector for delays in reviewing drug applications. The agency\'s capacity to conduct inspections, which came under criticism over the contaminated heparin incidents earlier this year (Marketletters passim), should be improved with the appointment of large numbers of technically-qualified personnel.

The largest contingent of the new recruits, 633 people, is for the Center for Drug Evaluation and Research, which assesses new agents and monitors the safety of pharmaceutical products already on the market. The food safety program will get 104. The enforcement division of the FDA gets 245 new personnel, after losing a large number of field officers in recent years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight